These findings suggest that SGLT2 inhibitors should lessen copeptin levels in line with improved fluid balance and cardiac and renal function in diabetes patients with CVD, a hypothesis that should be directly testable in the near future. This evidence concerns the gene SLC5A2 and diabetes mellitus.